[ad_1]
Webcast presentation on Thursday, April 4th 3:55 p.m. ET
The Woodlands, Texas, March 27, 2024 (GLOBE NEWSWIRE) — Autonomix Medical Inc. (Nasdaq: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies that revolutionize the diagnosis and treatment of diseases involving the nervous system, announced today Lori Beeson, CEO of Autonomix, will be attending MedInvest Biotech and Pharmaceutical Investor Conference Taking place on Thursday, April 4, 2024 at 3:55 PM ET in New York City, NY.
In addition to the presentation, management will participate in one-on-one meetings with members of the accredited investor community who have registered for the conference.For more information about the event, please visit Conference website.
A webcast Event details will be at Activity the page investor section of the company website (www.autonomix.com).
About Autonomix Medical, Inc.
Autonomix is a medical device company driving innovative technologies that revolutionize the diagnosis and treatment of diseases involving the nervous system. The company’s best-in-class technology platform includes catheter-based microchip sensing arrays that can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies. We believe this will enable, for the first time, transvascular diagnosis and treatment of diseases involving the peripheral nervous system anywhere in the body.
We are initially developing technology to target pancreatic cancer pain, a disease that causes debilitating pain and requires effective solutions. However, our technology forms a platform with the potential to address dozens of indications, including cardiology, renal denervation, and chronic pain management in a variety of diseases.
For more information, please visit autonomix.com and contact the company X, LinkedIn, Instagram and Facebook.
Investor and media contacts
JTC TEAM LLC
Jenny Thomas
833-475-8247
autonomix@jtcir.com
[ad_2]
Source link